Evorpacept + Venetoclax + Azacitidine for Acute Myeloid Leukemia

"Currently, this clinical trial is enrolling patients from 5 different sites. These locations are Buffalo, Chicago and Nashville in addition to 2 other cities. To reduce travel expenses for participants, it would be prudent to choose the closest medical centre."

"Evorpacept is a commonly used medication for induction chemotherapy. Furthermore, it has been effective in treating refractory anemias, leukemia, myelocytic forms of acute and multilineage dysplasia."

"As indicated on clinicaltrials.gov this trial, initially posted 5/5/2021 and last updated 6/7/2022, is not currently accepting new participants. Nonetheless, there are 1,879 other studies actively searching for volunteers at the moment."

"Unfortunately, this trial is no longer enrolling participants. It was initially posted on May 5th 2021 and had its last update on June 7th 2022. If you are looking for a different study to join, there are 1539 trials actively recruiting patients with leukemia or myeloid diseases and 340 studies that accept enrollees for evorpacept treatment."

"The initial research of evorpacept commenced at the Chinese University of Hong Kong-Prince of Wales Hospital in 2006, with 208 trials having been completed to date. Currently there are 340 ongoing investigations, and numerous sites located in Buffalo, New york are participating."